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Abstract
Background: Trauma is the number one killer of individuals 1–44 y of age in the United States. The prognosis and treatment
of inflammatory complications in critically injured patients continue to be challenging, with a history of failed clinical trials
and poorly understood biology. New approaches are therefore needed to improve our ability to diagnose and treat this
clinical condition.
Methods and Findings: We conducted a large-scale study on 168 blunt-force trauma patients over 28 d, measuring ,400
clinical variables and longitudinally profiling leukocyte gene expression with ,800 microarrays. Marshall MOF (multiple
organ failure) clinical score trajectories were first utilized to organize the patients into five categories of increasingly poor
outcomes. We then developed an analysis framework modeling early within-patient expression changes to produce a
robust characterization of the genomic response to trauma. A quarter of the genome shows early expression changes
associated with longer-term post-injury complications, captured by at least five dynamic co-expression modules of
functionally related genes. In particular, early down-regulation of MHC-class II genes and up-regulation of p38 MAPK
signaling pathway were found to strongly associate with longer-term post-injury complications, providing discrimination
among patient outcomes from expression changes during the 40–80 h window post-injury.
Conclusions: The genomic characterization provided here substantially expands the scope by which the molecular response
to trauma may be characterized and understood. These results may be instrumental in furthering our understanding of the
disease process and identifying potential targets for therapeutic intervention. Additionally, the quantitative approach we
have introduced is potentially applicable to future genomics studies of rapidly progressing clinical conditions.
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Trauma is the number one killer of individuals aged 1–44 y [1],
a source of some of the top health care costs in the United States
[2], and a major global health priority [3,4]. Trauma injuries
frequently lead to infections, sepsis, and multiple organ failure
(MOF) [5,6], which contribute to 51%–61% of late trauma
mortality [7]. A number of clinical trials for treating late trauma
complications have failed, believed partly due to the inability to
identify a proper patient population as well as the limited
understanding of the interplay of biological processes underlying
post-injury inflammatory complications [8,9]. A more compre-
hensive characterization of the genomic response to trauma is
therefore required in order to increase our understanding of the
molecular basis of clinical outcomes, leading to improvements in
diagnosis and treatment.
Despite the public health implications of improved trauma care,
relatively few studies have been carried out to understand the
molecular basis of trauma recovery, particularly from a genome-
wide perspective [10]. An endotoxin experiment on healthy
volunteers [11] and a retrospective sepsis study [12] have shown a
strong genomic response to trauma-related phenotypes. However,
to date there has been no in-depth, prospective longitudinal
characterization of the genome-wide expression response to blunt-
force trauma that (a) identifies which pathways are funda-
mental determinants of the patient’s recovery trajectory, and (b)
elucidates the time period post-injury when these molecular
signatures are most informative. Uncovering these factors can
reveal new therapeutic strategies and the dynamic regimens for
their administration.
To this end, the ‘‘Inflammation and the Host Response to
Injury’’ (IHRI) research program conducted a large-scale, 28-d
prospective clinical genomics study involving 168 patients, 797
microarrays, and 393 clinical variables. The key statistical
challenge we faced was how to accurately associate early
longitudinal gene expression measured at multiple time points
with 28 d clinical trajectories captured by a constellation of clinical
variables. We developed and applied a tractable and robust
quantitative framework to analyze this complex clinical genomics
study. Specifically, we sought to capitalize on the longitudinal
structure within an individual, combining bioinformatics and
statistical tools to elucidate pathway dynamics from the gene
expression data.
We found that approximately one quarter of the genome
changes during early stages of treatment in concordance with the
observed variation in 28-d clinical outcomes. These expression
changes are coordinated into five distinct modules, which together
provide a fine-scale separation of patient outcomes. We pinpointed
several pathways that appear to be key drivers of these modules
and may be instrumental in furthering our understanding of the
disease process and identifying potential targets for therapeutic
intervention [13,14]. We investigated the dynamics of these
pathways and found that several discriminate among 28-d post-
injury patients trajectories. Specifically, we identified p38 MAPK
signaling pathway and MHC-class II genes as having the strongest
discrimination in the first 40–80 h. Such information is potentially
useful in determining the exact timing and effective dosage of
drugs targeting these pathways in trauma patients.
A lack of reproducibility of clinical genomics results [15] has
been shown to be largely due to patient heterogeneity, latent
sources of confounding, and platform-dependent non-biological
variation [16], all difficult to deal with when associating clinical
outcome with a single snapshot of gene expression. Taking
advantage of the longitudinal design of our study, we developed
and applied an approach modeling ‘‘within-patient’’ gene
expression dynamics for extracting robust signatures, thereby
accounting for patient-specific effects and being more likely to
reproduce in future patients. Our framework is likely applicable to
other complex clinical genomics studies, especially in rapidly
progressing clinical conditions.
Methods
Study Design and Patient Samples
In the IHRI prospective clinical genomics study, we studied a
cohort of 168 patients (ages 16–55 y; 107 males) from a larger
epidemiological study, involving 1977 severe blunt-force trauma
patients, conducted from 2003 to 2011 through 7 U.S. Level I
trauma centers across the United States. Figure 1 provides the flow
chart leading to the 168 patients analyzed in this paper (epide-
miological study: ClinicalTrials.gov identifier: NCT00257231).
These 168 patients were followed for up to 28 hospital days post-
injury, and their longitudinal genome-wide gene expression was
measured. To ensure patients were at risk of developing MOF,
infectious complications, and death (thereby satisfying the study
requirements), the consortium employed a set of inclusion/
exclusion enrollment criteria (Text S1). Patients with isolated
traumatic brain injury were excluded. Samples were taken at fixed
time points following injury according to study design and
independent of physician influence. Thus there was no physician
or severity of illness bias in the sample collection process.
The institutional review board of each center approved the
study, and written informed consent was obtained from all patients
or their legal next of kin. The same standardized patient care
protocol was used to minimize the impact of variability in clinical
care across centers. Patient clinical information, typically consist-
ing of .300 variables (some longitudinal), was collected by trained
nurses and entered into a central database to maintain conformity
and consistency across all participating centers. For each patient,
genome-wide longitudinal gene expression was measured for total
blood leukocytes isolated from peripheral blood samples (collec-
tion, processing, and normalization described in Text S1 and
Figure S1). The data (de-identified as defined by the Health
Insurance Portability and Accountability Act of 1996; see http://
www.gluegrant.org/trdb.htm) are freely available at http://www.
gluegrant.org; see http://www.gluegrant.org/glueadmin/register
_consortium.jsp for details.
Figure 1. Patient selection for the IHRI study.
doi:10.1371/journal.pmed.1001093.g001
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Our proposed statistical framework (Figure 2), derived from two
a priori statistical hypotheses (Results), consists of three key steps:
Step 1. We used a time-dependent modified Marshall score
[17] (excluding the neurological component) as the measure of
developing MOF, providing an up-to-28-d Marshall score time
course trajectory for each patient. We applied hierarchical
clustering to the 168 patient Marshall score trajectories, yielding
five clusters (Figure 2, Step 1; Text S2). We used relevant patient
information, such as the 28-d mortality and morbidity rates, to
order these five subgroups (Figure 3; Table 1). This yielded a
clinically interpretable, ordered categorical MOF score (ocMOF)
ranging from i (good outcome) to v (bad outcome).
Step 2. For the gene expression analysis, we considered 126
patients with three or more arrays meeting the RNA quality
requirements among hours 12–250 (Text S2 and Figure S2). We
sought to characterize within-patient expression changes (WPEC)
by quantifying per hour log-fold change. To compute WPEC for
each probeset, we regressed log gene expression on time (in hours)
and extracted the linear slope (Figure 2, Step 2).
Step 3. We tested each probeset’s WPEC for an association
with ocMOF using an adjusted Spearman rank-based correlation
test and obtained a p-value for each probeset (Figure 2, Step 3;
Text S2). Associating WPEC with ocMOF through a rank-based
test enhances robustness, as WPEC values are used to establish an
ordering of directional changes across patients, but do not rely on
the actual magnitudes. Statistical significance of the 54,675
resulting p-values (Figure 4a) was assessed using the false
discovery rate (FDR) [18] yielding an estimate of the total
percentage of probesets associated with ocMOF as well as specific
probesets identified as significant at various FDR thresholds
(Figure 4b).
All the methodological, algorithmic, and data-filtering decisions
in Step 1 (clinical data) and in Step 2 (genomic data) were made
completely independently by two different analysts to avoid any
potential over-fitting.
Additional mathematical and algorithmic details about the
statistical methods can be found in Text S2. The R statistical
software environment (http://www.r-project.org/) was utilized to
perform all data analyses. Computer code that reproduces all
Figure 2. Schematic of the analysis framework. There are three fundamental steps in the analysis framework. Step 1: characterizing phenotypes
from longitudinal clinical data; Step 2: quantifying within-patient expression changes from the genomic data; and Step 3: statistical modeling and
hypothesis testing to relate the two.
doi:10.1371/journal.pmed.1001093.g002
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provided in Text S2.
PCA-Based Analysis of WPEC Matrix
To assess the overall effectiveness of WPEC in explaining
trauma response, we performed principal component analysis
(PCA) [19] on the WPEC matrix and determined the number of
principal components (PCs) via the scree plot. We used these PCs
as explanatory variables to model each of the 393 measured
clinical variables and identified the top ten most significant clinical
variables (Text S3).
Assessment of Reproducibility
We took a principled strategy to assess reproducibility (Figure 4c
and 4d). Our strategy (a) obtains the most significant probesets
using a ‘‘discovery set,’’ (b) computes their corresponding p-values
in a ‘‘validation set,’’ and (c) assesses whether the validation set p-
values show systematic, reproducible significance. We complete
Figure 3. Order of the ocMOF subgroups. The ordering can be determined with the following clinical variables: days from injury to discharge/
death, proportion of ICU-free days, and proportion of ICU ventilation–free days. Note that all patients in ocMOF v died.
doi:10.1371/journal.pmed.1001093.g003













Age 31.9610.7 35.5612.4 35.9610.5 34.1612.3 31.866.5 0.1264
a
Gender Female 28 (41%) 15 (47%) 16 (34%) 2 (12%) 0 (0%) 0.0128
b
Gender Male 40 (59%) 17 (53%) 31 (66%) 14 (88%) 5 (100%)
Design
Sampling Phase 1 12 (18%) 10 (31%) 14 (30%) 3 (19%) 3 (60%) 0.0041
b
Sampling Phase 2 24 (35%) 5 (16%) 9 (19%) 0 (0%) 0 (0%)
Sampling Phase 3 21 (31%) 8 (25%) 17 (36%) 8 (50%) 2 (40%)
Sampling Phase 4 11 (16%) 9 (28%) 7 (15%) 5 (31%) 0 (0%)
Outcomes
Death within 28 d 0 (0%) 0 (0%) 0 (0%) 2 (12%) 5 (100%) ,0.0001
b
Multiple organ failure 0 (0%) 1 (3%) 30 (64%) 16 (100%) 5 (100%) ,0.0001
b
Ventilator associated pneumonia 4 (6%) 7 (22%) 27 (57%) 12 (75%) 2 (40%) ,0.0001
b
Non-infectious complications 8 (12%) 21 (66%) 38 (81%) 15 (94%) 5 (100%) ,0.0001
b
Surgical site infections 6 (9%) 6 (19%) 14 (30%) 9 (56%) 2 (40%) ,0.0001
b
Nosocomial infections 15 (22%) 19 (59%) 40 (85%) 15 (94%) 3 (60%) ,0.0001
b
ICU tracheostomy 1 (1%) 2 (6%) 14 (30%) 5 (31%) 1 (20%) ,0.0001
b
Days from injury to discharge/death 15.3612.3 24.669.9 31.3615.2 48.4628.7 12.266.6 ,0.0001
a
Percentage of ICU-free days 60.1619.7 52.0618.9 30.9620.4 30.5620.9 4.068.9 ,0.0001
a
Percentage of ICU ventilator–free days 76.2617.1 65.2616.2 45.8621.1 38.3623.1 6.0613.4 ,0.0001
a
For non-categorical variables, the values represent the mean 6 standard deviation. For categorical variables, the values represent the total patients and the percentage
in the parentheses. To test for association and trend between the various variables and ocMOF as a numerical variable, the Spearman test (
a) and Deviance test (
b)o ft h e
logistic or multinomial model were used, as appropriate. Order of the ocMOF subgroups could be determined based on the data for the outcome variables.
doi:10.1371/journal.pmed.1001093.t001
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(0,1) distribution [18], which corresponds to the distribution of p-
values when there is no significance. We performed 20 cross-
validations by randomly splitting the study into discovery and
validation datasets (Text S3).
Dominant Expression Trajectories and Dynamic Co-
expression Modules
We utilized the DAVID software package to classify probesets
with FDR ,10% into 54 functionally related gene sets. We further
aggregated these gene sets into five modules according to the
similarity of their dominant trajectories across the ocMOF
subgroups (Text S4). We used the average Pearson correlation of
dominant trajectories across ocMOF subgroups as the similarity
metric. If the signs of these Pearson correlations were inconsistent
across ocMOF subgroups, then the similarity metric was set to
zero (no similarity). Next, we used Ward as the agglomeration
method and performed hierarchical clustering to obtain five
modules.
Specifically, to obtain the five dominant expression trajectories
for a gene set, we first removed patient–probeset-specific effects by
standardizing the gene expression values (scaling each patient
using the sample standard deviation of all of its probesets and
separately mean-centering each scaled probeset), and subsequently
fitted a loess curve to each ocMOF subgroup. These five dominant
trajectories were aligned to a common initial reference.
Figure 4. Statistical significance and reproducibility for the IHRIP data. (a) The histogram of 54,675 p-values from our framework. (b) The
number of significant probesets at various FDR cut-offs. These results indicate strong statistical significance. (c) Our strategy to assess reproducibility.
(d) Reproducibility assessment of our framework: 20 quantile-quantile plots for 20 cross-validations. Consistently large downward deviations from the
diagonal (dashed line) indicate reproducibility.
doi:10.1371/journal.pmed.1001093.g004
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by averaging the corresponding gene sets trajectories (Text S4).
We then applied Ingenuity Pathways Analysis (IPA) to identify
significant (p-value,0.002, after Bonferroni correction) canonical
pathways among the probesets making up each module. The exact
settings employed for DAVID and IPA are discussed in Text S4.
Results
We conducted a large-scale 28-d prospective clinical genomics
study involving 168 patients, 797 microarrays, and 393 clinical
variables (Methods) in order to understand the molecular basis of
clinical responses to trauma from a genome-wide perspective. To
this end, the central data-analytic challenge we faced was to
associate longitudinal gene expression and 28-d Marshall score
time course trajectories without over-fitting the data and while
maintaining clinical interpretability. To address this challenge, we
developed a within-patient longitudinal gene expression frame-
work (Figure 2), derived from the following a priori statistical
hypotheses: (a) there are several distinct trauma recovery
trajectories (or physiological responses to trauma), reflected in
the time varying clinical measures of interest, and (b) by using each
patient as her/his own internal control while modeling the gene
expression, inter-patient heterogeneity and confounding are
reduced. The framework collapses Marshall score trajectories into
clinically interpretable, ocMOF scores and longitudinal gene
expression into within-patient expression changes (WPEC). We
associated ocMOF and WPEC for each probeset using a rank-
based correlation test (Methods).
Composite Longitudinal ocMOF Score Captures Relevant
Clinical Variation
The ocMOF score is designed to capture the clinical variation
among patients across the 28-d treatment window (Table 1;
Figure 3; Text S5). Note that ocMOF is not introduced here to
replace standard clinical measures, but instead serves as a 28-d
longitudinal composite of overall patient variation and outcomes
in which the higher the score, the worse the patient experience.
The ocMOF i subgroup captures uncomplicated recovery with
minor or no inflammatory and infectious complications, whereas
ocMOF v group captures complications leading to MOF and death.
Figure 2, Step 1 shows the average Marshall score trajectories for
the five ordinal patient subgroups. Note, for example, that the
patients with ocMOF iii (0% mortality rate) and v (100% mortality
rate) have very similar Marshall score trajectories during the first
7-d (Figures S3 and S4), and hence are difficult to separate using
just Marshall scores (e.g., for the first 7-d mean Marshall scores,
the two-sample t-test p-value is 0.506).
WPEC Measure Robustly Captures Relevant Clinical
Variation
Instead of associating absolute expression values with ocMOF,
which is the de facto analysis strategy, we instead sought to
associate the within-patient change in gene expression with clinical
outcome. For each probeset and patient, a within-patient
expression change (WPEC) was formed by quantifying per-hour
log-fold change over hours 12–250 post injury (i.e., regressing log
gene expression on time and estimating the linear slope), which
was adequate (Text S6 and Figures S5 and S6).
We first performed a PCA-based analysis to assess the overall
effectiveness of WPEC in explaining trauma response (Text S6).
Eight PCs were obtained from the WPEC matrix (54,675
probesets by 126 patients), capturing 31% of total variation
(Figure S7a). Among the 393 clinical variables, those related with
Marshall and Denver scores are among the top ten most
significant clinical variables associated with these eight PCs
collectively, with ocMOF being the most significant (Table S1).
We repeated the same analysis on the mean expression matrix
(taking the mean across the time course, which effectively
combines baseline expression and WPEC) for hours 12–250
(eight PCs, 62% variation, Figure S7b) and found sampling phase
and trauma center among the ten most significant variables
(Table S2), implying patient-specific baseline expression is
susceptible to confounders.
Significance Analysis of WPEC Associations with 28-d
Trauma Outcome
We then performed a test of association between each probeset’s
WPEC measure and ocMOF to identify probesets that show a
statistically significant association with clinical outcome (Methods).
Both the resulting p-values (Figure 4a) and the FDR calculations
(Figure 4b) indicate strong statistical significance. This information
and mean WPEC for each ocMOF subgroup for all 54,675
probesets are provided in Table S3. The estimated percentage of
probesets associated [18] with ocMOF was $24%, indicating that
at least one-quarter of the genome undergoes early within-patient
expression changes associated with 28-d trauma outcome.
A lack of reproducible results has been a major hurdle for
translational research in clinical genomics [20,21]. With thousands
of genes tested for association and many being involved in the
disease, it is important to assess the reproducibility of our associa-
tion analysis. Therefore, we developed and applied a principled
cross-validation strategy to assess reproducibility of significance
(Figure 4c). We consistently observed small p-values for the top
100 probesets (Figure 4d), suggesting strong reproducibility of
significant associations.
Dynamic Co-expression Modules Discriminating Trauma
Outcome
We took a functional genomics approach to characterize the
dynamic expression variation driving the WPEC and trauma
outcome associations (Methods). We first applied DAVID [22,23],
a state-of-the-art classification algorithm that groups genes based
on their co-occurrences in annotation terms, to functionally cluster
1,256 of the 3,663 probesets with FDR ,10% (Table S4). We
further aggregated these gene sets into five modules according to
the similarity of their dominant trajectories across the ocMOF
subgroups (Figure S8). These modules were then organized in
descending order of their average pairwise similarity metric,
Module A (largest) to Module E (smallest); their dominant
trajectories are provided in Figures S9, S10, S11, S12, S13. The
average dominant trajectory of each ocMOF subgroup in each
module shows highly coordinated dynamic co-expression patterns
that discriminate the ocMOF groups in an ordered manner
(Figure 5), especially in the early time window post-injury.
We then applied IPA, a hand-curated database of biological
interactions and functional annotations, to identify statistically
significant canonical pathways among the probesets making up
each module (Methods). In general, the significant canonical
pathways within each module were relevant and related to
inflammation and immunity (see Figure 5 caption and Table S5).
Module A’s dominant trajectory for ocMOF v is notably different
from the other ocMOF subgroups, and its significant canonical
pathway is oxidative phosphorylation. Metabolic dysfunction from
trauma and infections has adverse effects on organ systems, and it
generally originates from the mitochondrion, which is involved in
the metabolism processes through oxidative phosphorylation
Inflammation by Within-Patient Expression Changes
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protein ubiquitination; targeting ubiquitin-mediated signaling is
thought to regulate nuclear factor-kB (NF-kB), currently of interest
as a therapeutic target in inflammatory diseases [26].
Key Pathways Associated with Trauma Outcome
To identify the key drivers of the genomic response to trauma,
we performed ontological analyses on the top 500 most significant
probesets using DAVID and IPA. For these 500 probesets, the
heatmap of all the gene expression data collected throughout the
study (stratified by day and ocMOF outcome) is provided in Figure
S14. We sought to identify gene sets that are enriched for
biological processes leading to poor trauma outcomes, show tightly
coordinated dynamic expression trajectories, and have strong
discriminatory power for post-injury MOF.
The top six canonical pathways (p-values,2.2610
25) identified
by IPA are dendritic cell maturation, Toll-like receptor (TLR)
signaling, p38 mitogen-activated protein kinase (p38 MAPK)
signaling, interleukin(IL)-6 signaling, production of nitric oxide
and reactive oxygen species in macrophages, and antigen
presentation (see Table S6 for the top 20). All six are involved
in cellular immune responses, implying a common theme. Two of
the pathways, TLR and p38 MAPK signaling, were recently
identified in a genome-wide expression study on early sepsis [12].
We applied DAVID to functionally cluster the top 500 probesets
(Table S7), yielding five gene groups that strongly support the IPA
results. Both analyses identified several genes that have been
individually targeted in previous model system studies [27,28]. We
discuss below two gene sets identified from the analyses, with
analogous results being shown for three others.
Antigen presentation pathway. The top gene group from
DAVID is enriched with the major histocompatibility complex
class II (MHC-II) genes, in which 16 of the 17 probesets in that
group are MHC-II, with four being in top 50. One of the top six
canonical pathways from IPA is antigen presentation (p-
value=2.2610
25), which also consists of MHC-II genes (Text
S7 and Figure S15). The MHC-II molecules are relevant to MOF
because they present foreign antigens on the cell surface, which is
essential for adaptive or innate immunity [29,30]. We used the 16
MHC-II probesets (representing HLA-DMB, HLA-DPA1, HLA-
DPB1, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB3,
HLA-DRB4, LOC100294318, and LOC100133678 genes)
identified by DAVID to comprise the MHC-II gene set for
subsequent analysis (Figure 6a–6c).
Figure 5. Dynamic co-expression modules and their dominant trajectories across the five ocMOF subgroups. We used DAVID to obtain
54 functionally related gene sets from the 3,663 most significant probesets (10% FDR), which were then clustered into five modules according to the
similarity of their dominant trajectories across the ocMOF subgroups. Modules A, B, C, D, and E contain 47, 37, 577, 231, and 364 probesets,
respectively. We applied IPA to identify enriched pathways within each module. This IPA analysis shortlisted the following pathways as statistically
significant (p-value,0.002, after Bonferroni correction; see Table S5): Oxidative Phosphorylation (Module A); RAN, IL-10 and IL-6 signaling, and the
Glycosphingolipid Biosynthesis-Lactoseries Pathway (Module C); Allograft Rejection Signaling, Antigen Presentation Pathway, Cytotoxic T
Lymphocyte-mediated Apoptosis of Target Cells, OX40 Signaling Pathway, Nur77 Signaling in T Lymphocytes (Module D); and Protein Ubiquitination
Pathway, Hypoxia Signaling, and Cleavage and Polyadenylation of Pre-mRNA in the Cardiovascular System (Module E). Note that Module A contains
47 probesets and one statistically significant pathway, and Module B contains 37 probesets and no statistically significant pathway.
doi:10.1371/journal.pmed.1001093.g005
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PLoS Medicine | www.plosmedicine.org 7 September 2011 | Volume 8 | Issue 9 | e1001093Figure 6. ocMOF and gene expression dynamics of MHC-II and p38 MAPK. For each ocMOF group, the dominant trajectory (thick colored
line) was obtained by averaging all the standardized MHC-II (a) and p38 MAPK (d) probesets trajectories (gray lines) of patients within the ocMOF
subgroup. Generally, the dominant trajectory for MHC-II increases with time for ocMOF i and ii, initially decreases and then increases for ocMOF iii, and
decreases for ocMOF iv and v. For p38 MAPK, the early dominant trajectory decreases with time for ocMOF i and ii, initially increases and then
decreases for ocMOF iii, and increases for ocMOF iv and v. The dominant trajectories within the first 100 h suggest that early expression changes (gray
region) of MHC-II (b) and p38 MAPK (e) correlate with patient outcome. The number of up-regulated MHC-II (c) and p38 MAPK (f) probesets
(computed using the two sampling time points closest to the 40–80 h post-injury interval) separates patients with ocMOF i, ii, and iii from patients
with ocMOF iv and v (p-value of the Kruskal-Wallis test is 0.00004 for MHC-II and 0.00668 for p38 MAPK).
doi:10.1371/journal.pmed.1001093.g006
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v, the WPEC decreases for all 16 MHC-II probesets, exhibiting a
dosage effect (Figure S16). The dominant expression trajectories
also exhibited a similar trend (Figure 6a). The difference among
dominant trajectories is particularly pronounced during the 40–
80 h window, suggesting that early expression changes can be used
to discriminate among the patient ocMOF scores (Figure 6b).
Using the two time points closest to 40–80 h post-trauma, we
counted the number of up-regulated MHC-II probesets within
each patient, and observed consistently high counts for ocMOF i, ii,
and iii and low counts for ocMOF iv and v (Figure 6c).
p38 MAPK signaling pathway. All of the top five canonical
pathways from IPA contain the mitogen-activated protein kinase
14 (MAPK14) gene, and all four probesets representing it are
among the top 500 with three being in top 50. The MAPK14 gene
is an isoform of the p38 MAPK gene, the signaling pathway of
which (one of the top five canonical pathways, Figure S17) is
known to play an important role in driving the inflammatory
response to either microbial products (via PAMPs), endogenous
danger signals (via DAMPs or alarmins), and pro-inflammatory
cytokines by phosphorylating transcription factors, resulting in the
further expression of inflammatory mediators [31,32,33]. This
suggests that the p38 MAPK signaling pathway is an integral
signaling mechanism for the other top five canonical pathways and
hence the presence of MAPK14 in those pathways. Using IPA, we
obtained an additional eight (out of the top 500) probesets
representing the genes involved in the p38 MAPK signaling
pathway (Text S7), giving us the p38 MAPK gene set (12
probesets, representing MAPK14, CREB5, IL1R1, IL1RN,
IRAK2, IRAK3, MAP2K6, and TIFA) for further analysis
(Figure 6d–6f).
For the p38 MAPK probesets, we observed a trend opposite
that of the MHC-II probesets. Generally, WPEC increased in
moving from ocMOF i to v (Figure S18), and the early dominant
trajectories also discriminated the ocMOF groups (Figure 6e–6f).
A similar analysis was performed on three other gene sets,
representative of the remaining top six canonical pathways,
suggesting trends similar to those of p38 MAPK (Text S7 and
Figures S19, S20, S21, S22, S23, S24).
Using a controlled endotoxin experiment dataset [11], which
served as a corroborative experiment, we obtained dominant
trajectories for MHC-II and p38 MAPK among healthy
individuals administered with endotoxin (Text S7). The trends of
these trajectories from $5 h were similar to those seen with
ocMOF i and ii (Figure S25).
Discussion
In this paper we have provided a comprehensive analysis of the
longitudinal IHRIP study, taking into account all major sources of
collected data. Despite inherent complexities in clinical genomic
data, we showed that robust and relevant genomic signatures can
be obtained with our framework, aimed at facilitating straightfor-
ward translation into a clinical setting. Our results have
implications for the design and analysis of future large-scale
clinical genomics studies.
We showed that clinical association using WPEC is straight-
forward to calculate and appears to be robust to confounders.
Our framework collapses Marshall score trajectories and
longitudinal gene expression into clinically interpretable quanti-
ties, permitting reliable statistical modeling without over-fitting
the data. Using our framework we identified genes whose WPEC
discriminate among the ocMOF outcomes. One of the main
advantages of utilizing WPEC is that it leads more directly than
do other measures to a clinical translation of the results, because
it captures the change in expression within a patient, regardless of
the patient’s baseline value, which is susceptible to patient
heterogeneity, confounders, and technical effects. On the other
hand, any snapshot, baseline, or average expression profile will be
susceptible to these effects. We repeated the above analyses using
both an estimate of the hour 12 expression value and the average
over the entire time course. Both measures showed evidence of
being influenced by confounders (particularly batch and trauma
center effects), and neither produced biological significance
greater than WPEC.
We performed a global functional genomics analysis of the top
3,663 statistically significant WPEC associations with trauma
outcome (FDR=10%), identifying five dynamic co-expression
modules highly enriched for immune pathways. We also
performed a more focused pathway analysis of the top 500
associations (FDR=0.6%) and identified a number of relevant
gene sets. We pinpointed the MHC-II and p38 MAPK gene sets,
showing that their expression dynamics suggest their potential as
biomarkers. Moreover, our analysis suggests that the strongest
discrimination occurs in the first 40–80 h post-injury.
From the dynamic co-expression modules results, one can
consider the configuration of ocMOF-specific trajectories within
and among these modules along with the biological significance of
the modules to construct a spectrum of biologically relevant gene
expression variation discriminating the clinical outcomes (ocMOF
i to v). For example, our module-based analysis pointed to the NF-
kB pathway. Previous studies have indicated that this pathway,
which is downstream of the TLR, is critical in the context of post-
traumatic immune dysfunction-induced poor outcomes [34,35].
Taken as a whole, this systems analysis revealed a large and
coordinated gene expression response to trauma, characterized by
the modules and gene sets, indicating that something is to be
gained from a systems-level understanding [36] of the molecular
biology of post-injury MOF in forming therapeutic targets and
prognostic procedures.
Our findings on the down-regulation of MHC-II genes among
patients from ocMOF iv to v are consistent with persistently low
HLA-DR expression that has been associated with septic
complications [37,38], because a marked depression of cell-
mediated immune function (i.e., immunosuppression) is believed
to play a role in sepsis after severe trauma. HLA-DR is a
promising molecular surrogate marker for treating post-injury
inflammatory complications [39], and monitoring HLA-DR
expression to treat trauma patients with immunomodulatory
drugs such as interferon-c has been studied. Importantly, our
genome-wide approach suggests the association of the entire
MHC-II gene set (represented by 16 probesets, Kruskal-Wallis p-
value=0.00004, Figure 6c), besides HLA-DR (represented by five
of these 16 probesets, Kruskal-Wallis p-value=0.00029), may be
more informative. Persistent systemic inflammatory response
syndrome (SIRS) is shown to be predictive of nosocomial infection
in trauma patients [40,41], which is consistent with the up-
regulation of genes in the p38 MAPK signaling pathway among
patients from ocMOF iii to v.
It has been posited that MOF is an outcome of an inappropriate
generalized inflammatory response, involving the interplay
between mediators (e.g., cytokines and chemokines) and effector
cells (e.g., neutrophils and macrophages) [42]. The SIRS and
compensatory response syndrome (CARS) are proposed to be
involved in the etiology of MOF [7]. It may well be that the
increase in p38 MAPK expression seen here after severe trauma
reflects the development of SIRS while a persistent decrease in
MHC-II expression reflects the development of CARS (Text S8),
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Beyond the definitions of CARS and SIRS, the modern concept of
post-traumatic immune suppression is also believed to be a major
cause of secondary infections or organ dysfunction [43,44].
Although it was to date the largest clinical genomic study on
trauma response of which we are aware, the current study has
certain limitations. Since gene expression was measured for total
blood leukocytes isolated from peripheral blood samples, some of
the differential expression changes identified could be confounded
by changes in individual leukocyte subpopulations. Arguably, the
predictive utility of the identified biomarkers still exists.
In this study, we identified relevant pathways and gene sets
showing a coordinated pattern of expression variation associated
with response to trauma at a genome-wide scale. These findings
potentially provide the most comprehensive picture of the gene
expression response to trauma to date, thereby demonstrating the
power of moving beyond candidate gene studies [45] of this
clinical condition. The expression variation at the genomic level
that we have characterized among patients may help to provide a
more comprehensive set of drug targets and a means to identify
relevant subsets of patients for which these may be effective.
Supporting Information
Dataset S1 Annotated scripts that reproduce the results
in the paper. The scripts run the entire analysis in R statistical
software (cran.r-project.org). See Text S2 for the details and
http://genomine.org/trauma/ for instructions on obtaining the
full dataset.
( )
Figure S1 Microarray collection time points by patient.
X-axis is the time from injury and Y-axis patient IDs. Each circle
represents a microarray collected. Intended sampling was on days
0, 1, 4, 7, 14, 21, and 28 since injury, but depending on the total
days from injury to discharge/death, the number of microarrays
per patient ranged between 2 to 7.
(PDF)
Figure S2 Heatmap of patient–patient correlations.
Using the WPEC matrix we computed patient–patient
correlations for 129 patients. The heatmap of dichotomized
correlations (black=negative; gray=positive) identified two
patients as outliers with completely opposite correlations from
the rest. We removed these two patients due to potential array
quality issues.
(PDF)
Figure S3 Heatmap of the modified Marshall scores on
day 0, 2, 3, …, 20 and the dendrogram of the
hierarchical clustering. Hierarchical clustering was performed
on the modified Marshall score trajectories, where missing scores
were imputed using k-nearest neighbor. The left plot is the
dendrogram of the hierarchical clustering from which we obtained
five subgroups: ocMOF i to v. Patients from ocMOF i to iii tend to
have low modified Marshall scores, with patients with ocMOF
i recovering to 0 first, followed by ocMOF ii and iii, while patients
from ocMOF iv and v tend to have high modified Marshall scores
throughout the first 20 d.
(PDF)
Figure S4 Marshall score trajectories and ocMOF. Thin
dashed lines in gray correspond to patient-specific Marshall score
trajectories, and thick solid lines to the mean trajectories of the
ocMOF subgroup. Only the observed modified Marshall scores
are used to make these plots, but the actual clustering was
performed on imputed data. Note that four out of five patients
with ocMOF v died on or before day 10 post-injury, and that the
red dashed line is for the remaining patient who died on day 24
post-injury. Mean ocMOF trajectories, together with other
relevant patient clinical information, allowed us to order the
ocMOF clusters in terms of overall patient severity. In particular,
ocMOF i=good outcome (fast and uncomplicated recovery) and
ocMOF v=very bad outcome (death).
(PDF)
Figure S5 Probesets with different dynamics. (a–d)
Expression trajectory of probesets in the time window 0–250 h
(shown in a and c) and 12–250 hours (shown in b and d). Patient-
specific trajectories are represented by gray lines, and population
average trajectories and population average linear trajectories are
represented by the black and red lines respectively. (a) and (b)
correspond to the most non-significant probeset from the DWPEC
analysis, where the differences between the average trajectory and
average linear trajectory are minimal. (c) and (d) correspond to the
most significant probeset from the DWPEC analysis, where the
differences between the average trajectory and average linear
trajectory are large in time window 0–250 h but are reduced in
time window 12–250 h.
(PDF)
Figure S6 Reasoning to exclude hours ,12. Boxplots of
mean-square difference (MSD) between the population average
trajectory and average linear trajectory for the 5,000 most non-
significant (ns) and significant (sig) probesets from the DWPEC
analysis. We investigated the MSD for four different time
windows: hour 0–250, hour 4–250, hour 8–250 and hour 12–
250. The MSDs for the non-significant probesets are very similar
across all four time windows, but the MSDs for the significant
probesets are generally high for hour 0–250 and tend to decrease
as we progressively exclude the early hours.
(PDF)
Figure S7 The scree plots to determine the number of
principal components. (a) corresponds to the WPEC matrix
and (b) to the mean expression matrix.
(PDF)
Figure S8 The dendrogram for grouping the 54 func-
tional related gene sets into five modules according to
the similarity of their dominant trajectories across the
ocMOF subgroups.
(PDF)
Figure S9 The dominant trajectories for Module A. For
each ocMOF subgroup, where (a)–(e) correspond to ocMOF i to v,
the dominant trajectories of the module (thick colored lines) are
obtained by averaging all dominant trajectories of gene sets
belonging to the module (gray lines). (f) plots all five ocMOF
subgroup dominant trajectories for Module A in one plot by
aligning them to a common initial reference.
(PDF)
Figure S10 The dominant trajectories for Module B. See
the caption for Figure S9 for details.
(PDF)
Figure S11 The dominant trajectories for Module C. See
the caption for Figure S9 for details.
(PDF)
Figure S12 The dominant trajectories for Module D. See
the caption for Figure S9 for details.
(PDF)
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ZIPFigure S13 The dominant trajectories for Module E. See
the caption for Figure S9 for details.
(PDF)
Figure S14 The heatmap of ranked gene expressions for
all 168 patients over 28 d for the 500 most significant
probesets from our analysis. For each probeset, we ranked
the expression values across all 168 patients over 28 d, i.e. 797
microarrays (green=low rank, black=average rank, red=high
rank). The columns are microarrays ordered by days, and within
each day by ocMOF values. The intended sampling was on days 0,
1, 4, 7, 14, 21, and 28 since injury.
(PDF)
Figure S15 The antigen presentation pathway. The
MHC-II genes have negative spearman correlation coefficients
between WPEC and ocMOF (colored blue).
(PDF)
Figure S16 ocMOF and gene expression dynamics of
MHC-II. (a) Boxplots of WPEC versus ocMOF indicate a
negative dosage effect as we go from ocMOF i to v (p-value of the
Spearman’s test ,10
215). (b) For each ocMOF group, the
dominant trajectory (thick colored line) was obtained by averaging
all the standardized MHC-II probeset trajectories (gray lines) of
patients within the ocMOF subgroup. Generally, the dominant
trajectory increases with time for ocMOF i and ii, initially decreases
and then increases for ocMOF iii, and decreases for ocMOF iv and v.
Both WPEC and the dominant trajectories exhibit similar trend.
(c) The dominant trajectories within the first 100 h suggest that
early expression changes (gray region) correlate with patient
outcome. (d) The number of up-regulated MHC-II probesets
(computed using two time points near hour 40–80) separates
patients with ocMOF i, ii, and iii from patients with ocMOF iv and v
(p-value of the Kruskal-Wallis test is 0.00004).
(PDF)
Figure S17 The p38 MAPK signaling pathway. Among the
top 500 probesets, 15 are in this canonical pathway (representing
11 genes). Those genes in blue and red have negative and positive
Spearman correlation coefficients between WPEC and ocMOF,
respectively. TRADD, MEF2, and Max were removed from
further analysis because their correlations were inconsistent with
those identified by IPA.
(PDF)
Figure S18 Gene expression profiles of the 12 probesets
involved in the p38 MAPK signaling pathway. (a) Boxplots
of WPEC versus ocMOF indicate a positive dosage effect as we go
from ocMOF i to v (p-value of the Spearman’s test ,10
215). (b) For
each ocMOF group, the dominant trajectory (thick colored line)
was obtained by averaging all the standardized p38 MAPK
probeset trajectories (gray dotted lines) of patients within the
ocMOF subgroup. Generally, the early dominant trajectory
decreases with time for ocMOF i and ii, initially increases and
then decreases for ocMOF iii, and increases for ocMOF iv and v.
Both WPEC and the dominant trajectories exhibit similar trends.
(c) The dominant trajectories within the first 100 h suggest that
early expression changes (gray region) correlate with patient
outcome. (d) The number of up-regulated p38 MAPK probesets
(computed using two time points near hour 40–80) separates
patients with ocMOF i, ii, and iii from patients with ocMOF iv and v
(p-value of the Kruskal-Wallis test is 0.00668).
(PDF)
Figure S19 The Toll-like receptor (TLR) pathway.
Among the top 500 probesets, 12 are in this canonical pathway
(representing nine genes). Those genes in blue and red have
negative and positive Spearman correlation coefficients between
WPEC and ocMOF, respectively. JNK1 was removed from
further analysis because its correlation was inconsistent with that
identified by IPA.
(PDF)
Figure S20 Gene expression profiles of probesets in-
volved in the TLR pathway. Similar to p38 MAPK signaling
pathway. See Figure S18 for details. Altogether 11 probesets
(representing eight genes) were used for this pathway. For (a) the
p-value of the Spearman’s test ,10
215 and for (d) the p-value of
the Kruskal-Wallis test is 0.02092.
(PDF)
Figure S21 The Interleukin (IL)-6 signaling pathway.
Among the top 500 probesets, 14 are in this canonical pathway
(representing ten genes). Genes in blue and red have negative and
positive Spearman correlation coefficients between WPEC and
ocMOF, respectively. JNK was removed from further analysis
because its correlation was inconsistent with that identified by IPA.
(PDF)
Figure S22 Gene expression profiles of probesets in-
volved in the IL-6 signaling pathway. Similar to p38 MAPK
signaling pathway. See Figure S18 for details. Altogether 13
probesets (representing nine genes) were used for this pathway. For
(a) the p-value of the Spearman’s test ,10
215 and for (d) the p-
value of the Kruskal-Wallis test is 0.00898.
(PDF)
Figure S23 The production of nitric oxide and reactive
oxygen species in macrophages pathway. Among the top
500 probesets, 18 are in this canonical pathway (representing 13
genes). Genes in blue and red have negative and positive
Spearman correlation coefficients between WPEC and ocMOF,
respectively. JNK and PP1/PP2a were removed from further
analysis because their correlations were inconsistent with those
identified by IPA. IkB and p38 MAPK were removed because of
their complexity in this pathway.
(PDF)
Figure S24 Gene expression profiles of probesets in-
volved in the production of nitric oxide and reactive
oxygen species in macrophages pathway. Similar to p38
MAPK signaling pathway. See Figure S18 for details. Altogether
11 probesets (representing nine genes) were used for this pathway.
For (a) the p-value of the Spearman’s test ,10
215 and for (d) the
p-value of the Kruskal-Wallis test is 0.01370.
(PDF)
Figure S25 Gene expression profiles of MHC-II and p38
MAPK in a controlled endotoxin experiment. (a,b) The
mean of the log-expression of MHC-II (a)a n dp 3 8M A P K( b).
The black and red lines correspond to the healthy patients
administered with placebo and endotoxin, respectively. After
hour 5 (the region to the right of the dotted vertical line), the
mean trajectories corresponding to healthy patients administered
with endotoxin are similar to the dominant trajectories of ocMOF
i and ii.
(PDF)
Table S1 The ten most significant clinical variables (out
of 393) associated with the eight principal components
from the WPEC matrix. Legend: *Clinical variables are
treated as categorical variables, and R
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of 393) associated with the eight principal components
from mean expression matrix. Legend: *Clinical variables





Table S3 Ranking of the 54,675 probesets according to
the significance analysis of WPEC associations with 28-d
trauma outcome.
(XLS)
Table S4 Fifty-four functional related gene sets from
DAVID for the 3,663 significant (FDR=10%) probesets.
(XLS)
Table S5 The top five canonical statistically signifi-
cant (p-value,0.002, after Bonferroni correction)
pathways for the five dynamic co-expression modules.
For each canonical pathway we report the p-value of Fisher’s
e x a c tt e s tt h a ta s c e r t a i n se n r ichment and the proportion of
genes in the pathway that were actually in the module within
the brackets, and the gene names (in italics). Note that N.A.
denotes no significant pathways with three or more genes were
identified.
(PDF)
Table S6 The top 20 canonical pathways for the top 500
probesets from WPEC and ocMOF association analysis
(IPA, obtained May 2010). Legend: p, p-value of Fisher’s exact
test for ascertaining enrichment; and ratio, the proportion of genes
in the pathway that are in the top 500.
(PDF)
Table S7 Detailed resultsof DAVID analysis on the top 500
probesets from WPEC and ocMOF association analysis.
(PDF)
Text S1 Inclusion/exclusion criteria and gene expression
information.
(PDF)
Text S2 Additional details on statistical framework.
(PDF)
Text S3 Details on assessing WPEC robustness and reproducibility.
(PDF)
Text S4 Details on module, pathway, and gene set analysis.
(PDF)
Text S5 Marshall MOF-derived clinical outcomes.
(PDF)
Text S6 Results on assessing WPEC robustness.
(PDF)
Text S7 Key pathways associated with trauma outcomes.
(PDF)
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Background. Trauma—a serious injury to the body caused
by violence or by an accident—is a major global health
problem. Every year, events that include traffic collisions,
falls, blows, and fires cause injuries that kill more than 5
million people (9% of annual global deaths). Road traffic
accidents alone are responsible for 1.3 million deaths a year
and, if current trends continue, will be the fifth leading cause
of death worldwide by 2030. Moreover, in many countries,
including the US, trauma is the number one killer of
individuals aged 1–44 y. Trauma can kill people rapidly
through loss of blood or serious physical damage to internal
organs, but it can also lead to localized infections and to
sepsis, an infection of the bloodstream that is characterized
by an amplified, body-wide (systemic) inflammatory
response. Inflammation—redness, pain, and swelling—is an
immune system response that normally provides protection
against infections, but systemic inflammation can result in
multiple organ failure (MOF) and death.
Why Was This Study Done? Inflammatory complications
of trauma are responsible for more than half of late trauma
deaths, but at present it is impossible to predict which
patients with major injuries will recover and which will spiral
down into MOF and death, because the biological processes
that underlie post-injury inflammatory complications are
poorly understood. If the changes in gene expression (the
process that converts the information encoded in genes into
functional proteins) that accompany systemic inflammation
could be elucidated, it might be possible to improve the
diagnosis of MOF and to develop better treatments for post-
trauma inflammatory complications. In this prospective,
longitudinal clinical genomics study (part of the Inflammation
and Host Response to Injury multi-disciplinary research program
[IHRI]), the researchers developed an approach to associate early
within-patient gene expression changes with later clinical
outcomes. A prospective study is one in which patients with a
specific condition are enrolled and then followed to see how
various factors affect their outcomes; a longitudinal study
analyzes multiple samples taken at different times from
individual patients; a clinical genomics study investigates how
genes and gene expression affect clinical outcomes.
What Did the Researchers Do and Find? The researchers
followed 168 patients for up to 28 d after they experienced
blunt-force trauma (injuries caused when the human body
hits or is hit by a large object such as a car). Using a
molecular biology tool called a DNA microarray, they
determined gene expression patterns in leukocytes (a type
of immune system cell) isolated from multiple blood samples
collected from each patient during the first few days after
injury. Using clinical information collected by trained nurses,
they organized the patients into five outcome categories
based on a measure of MOF known as the Marshall score.
Finally, they developed a statistical method (an analysis
framework) to associate the early changes in gene
expression with clinical outcomes.
A quarter of the patients’ genes showed early expression
changes that were associated with longer-term post-injury
inflammatory complications. Among the associations re-
vealed by this analysis, down-regulation (reduced expres-
sion) of MHC-class II genes (which encode proteins involved
in antigen presentation, the process by which molecules
from foreign invaders are presented to immune cells to
initiate an immune response) and up-regulation of genes
encoding components of the p38 MAPK signaling pathway
(which helps to drive inflammatory responses) between 40
and 80 h post-injury were particularly strongly associated
with longer-term post-injury complications and provided the
strongest discrimination between patient outcomes.
What Do These Findings Mean? The statistical approach
used in this study to link the early changes in gene
expression that occur after trauma to clinical outcomes
provides a detailed picture of genome-wide gene expression
responses to trauma. These findings could help scientists
understand why some patients develop inflammatory
complications of trauma while others do not, and they
could help to identify those patients most at risk of
developing complications. They could also help to identify
targets for therapy, although further studies are needed to
confirm and extend these findings. Importantly, the
quantitative approach developed by the researchers for
analyzing associations between within-patient gene changes
over time and clinical outcomes should provide more robust
predictions of outcomes than single measurements of gene
expression and could be applicable to genomic studies of
other rapidly progressing clinical conditions.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001093.
N More details about the Inflammation and Host Response to
Injury research program are available; the program’s
website includes a link to an article that explains how
genomics can be used to understand the inflammatory
complications of trauma
N The World Health Organization provides information on
injuries and on violence and injury prevention (in several
languages)
N The US National Institutes of Health has a factsheet on
burns and traumatic injury in the USA
N The US Centers for Disease Control and Prevention has
information on injury and violence prevention and control
N MedlinePlus provides links to further resources on injuries
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